Paula C Mahoney

age ~72

from Salt Lake City, UT

Get Report

Also known as:

Connected to:

Paula Mahoney Phones & Addresses

Fractionated Light Pdt Therapy For Posterior Eye Disease
view source
US Patent:

20050240247, Oct 27, 2005
Filed:

Mar 25, 2005
Appl. No.:

11/089944
Inventors:

Brian McIlroy - Sammanish WA, US
Gregory Heacock - Auburn WA, US
Paula Mahoney - Woodinville WA, US
Andrew Hamilton - Pinner, GB
International Classification:

A61N005/06
US Classification:

607088000
Abstract:

A method and system directs therapeutic light of a first wavelength to a patient's eye to excite a photosensitizing agent for PDT during a series of discrete periods of time that are separated by non-therapeutic intervals. Diagnostic light of a second wavelength can be directed to the eye during at least a portion of one or more of the non-therapeutic intervals to allow a physician to see the affect of the therapy.

Low Energy Of Excitation Pdt Compounds For Treatment Of Ocular Disease
view source
US Patent:

20060084951, Apr 20, 2006
Filed:

Sep 30, 2005
Appl. No.:

11/240403
Inventors:

Gregory Heacock - Auburn WA, US
John Marshall - Farnborough, GB
Paula Mahoney - Woodinville WA, US
International Classification:

A61B 18/18
US Classification:

606004000, 607088000
Abstract:

A photodynamic therapy includes a particular combination of a photosensitizer and light source for a photodynamic therapy used to treat ocular diseases. The photosensitizer has a peak excitation level when exposed to light of a given wavelength where the wavelength of light is absorbed at a particular location of the eye to be treated. The light source has a wavelength within the excitation range of the photosensitizer and matched to the location of the diseased eye tissue. The light source also has an irradiance level and energy level that is effective for therapy but at levels below the maximum permissible exposure level.

Enhanced Occlusive Effect Photodynamic Therapy
view source
US Patent:

20060229284, Oct 12, 2006
Filed:

Dec 13, 2005
Appl. No.:

11/301743
Inventors:

Paula Mahoney - Woodinville WA, US
Louise Culham - Auburn WA, US
Brian McIlroy - Sammamish WA, US
Gregory Heacock - Auburn WA, US
Andrew Hamilton - Pinner, GB
John Marshall - Farnborough, GB
International Classification:

A61K 31/409
A61K 31/555
A61H 33/00
US Classification:

514185000, 514410000, 607086000
Abstract:

This invention discloses methods of treating neovasculature diseases of the eye through the administration of a photosensitizing agent and subsequent exposure to light of specific wavelength sufficient to photoactivate the photosensitizing agent to occlude one or more vessels in the neovasculature for an extended period of time. Diseases treatable under this invention, include, for example: diabetic retinopathy; macular degeneration; subfoveal choroidal neovascularization, malignant uveal melanomas and other maladies of the human or animal eye or body.

Extended Treatment Of Tumors Through Vessel Occlusion With Light Activated Drugs
view source
US Patent:

20090192209, Jul 30, 2009
Filed:

Jan 7, 2005
Appl. No.:

11/663695
Inventors:

Paula A. Mahoney - Woodinville WA, US
Hongxia Xu - Bellevue WA, US
Michael Alan Krouse - Seattle WA, US
Yan Liang - Bellevue WA, US
Myron Jay Winship - North Bend WA, US
Assignee:

Light Sciences Oncology, Inc. - Bellevue WA
International Classification:

A61K 31/40
US Classification:

514410
Abstract:

Methods of treating diseases of a subject through selective occlusion of blood vessels. The methods include identifying and/or mapping the blood vessels supplying nutrients to the diseased or unwanted tissue, delivering an appropriate dose of an occlusion-forming photosensitizer to the subject, and exciting the photosensitizer with sufficient light irradiation in the vicinity of the blood vessels to cause vessel occlusion. The vessel occlusion cuts off nutrient supply to the diseased or unwanted tissue resulting in cell death of that tissue and any other tissue served by the occluded vessels.